KIR expression and STAT3 mutational status in CLPD-NK patients
| Patient code no. . | Mutation status . | Abnormal KIR expression . | Reference . |
|---|---|---|---|
| 2-color flow cytometry | |||
| 3 | No | Yes | Present study |
| 5 | No | Yes | 23 |
| 6 | No | Yes | Present study |
| 10 | N647I | Yes | Present study |
| 11 | No | Yes | Present study |
| 12 | No | Yes | Present study |
| 13 | Y640F | Yes | 23 |
| 15 | No | Yes | Present study |
| 17 | No | Yes | Present study |
| 18 | No | Yes | Present study |
| 19 | No | Yes | Present study |
| 20 | No | Yes | 23 |
| 22 | No | Yes | 23 |
| 23 | D661I | Yes | Present study |
| 28 | No | Yes | 23 |
| 34 | D661Y | Yes | Present study |
| 36 | Y640F | Yes | 23 |
| 38 | No | Yes | Present study |
| 4-color flow cytometry | |||
| 63 | Y640F | Yes | Present study |
| 83 | No | Yes | Present study |
| 47 | D661Y | Yes | Present study |
| 57 | No | Yes | Present study |
| 61 | No | No | Present study |
| 62 | No | No | Present study |
| 74 | No | Yes | Present study |
| Patient code no. . | Mutation status . | Abnormal KIR expression . | Reference . |
|---|---|---|---|
| 2-color flow cytometry | |||
| 3 | No | Yes | Present study |
| 5 | No | Yes | 23 |
| 6 | No | Yes | Present study |
| 10 | N647I | Yes | Present study |
| 11 | No | Yes | Present study |
| 12 | No | Yes | Present study |
| 13 | Y640F | Yes | 23 |
| 15 | No | Yes | Present study |
| 17 | No | Yes | Present study |
| 18 | No | Yes | Present study |
| 19 | No | Yes | Present study |
| 20 | No | Yes | 23 |
| 22 | No | Yes | 23 |
| 23 | D661I | Yes | Present study |
| 28 | No | Yes | 23 |
| 34 | D661Y | Yes | Present study |
| 36 | Y640F | Yes | 23 |
| 38 | No | Yes | Present study |
| 4-color flow cytometry | |||
| 63 | Y640F | Yes | Present study |
| 83 | No | Yes | Present study |
| 47 | D661Y | Yes | Present study |
| 57 | No | Yes | Present study |
| 61 | No | No | Present study |
| 62 | No | No | Present study |
| 74 | No | Yes | Present study |
Abnormal KIR expression included homogeneous reactivity to a single KIR receptor and/or absence of reactivity to 1 or more KIR receptors.